BioCoR also has an impact in regulation, standards, guidance, and best practice of preservation such as logistics, supply chain, and workflow for cell therapies and regenerative medicine products. This spans from R&D and academia, clinical trials, manufacturers, and in hospital/clinic workflow. We have worked with the FDA, AABB, FACT, and ISBER.
Bringing it back... to the community: banking on diversity and sharing / all of us spotlight - Allison Hubel, Rita Lawlor, Billy Schleif, ISBER 2019
Tangled up in trypan blue: living biobanks - Allison Hubel, Xuefeng Liu, ISBER 2019
Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative - Minoko Takanashi, Eileen Selogie, Jo-Anna Reems, David Stroncek, Magali J Fontaine, John Girdlestone, Henk S P Garritsen, Pampee Young, David H McKenna, Zbigniew M Szczepiorkowski
Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations - D Nicole Worsham, Jo-Anna Reems, Zbigniew M Szczepiorkowski, David H McKenna, Thomas Leemhuis, Aby J Mathew, Jose A Cancelas
Storage of Human Biospecimens: Selection of the Optimal Storage Temperature - Allison Hubel, Ralf Spindler, and Amy P.N. Skubitz
State of the art in preservation of fluid biospecimens - Allison Hubel, Alptekin Aksan, Amy P N Skubitz, Chris Wendt, Xiao Zhong